Lercanidipine Arrow

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Arrow, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension by causing vasodilation and reducing peripheral vascular resistance.

GNH USA supplies Lercanidipine Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Lercanidipine is a dihydropyridine calcium channel blocker used in the management of hypertension. - Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Essential hypertension: provides sustained blood pressure control when monotherapy is required. - High blood pressure: contributes to cardiovascular risk reduction by maintaining target blood pressure levels.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often occurring early in therapy. - Flushing: sensation of warmth and redness, typically transient. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: may occur with standing, especially after dose initiation. - Tachycardia: increased heart rate in some patients. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, itching, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy with Lercanidipine, consider the following precautions. - Monitor blood pressure: check regularly after dose changes or initiation. - Avoid abrupt discontinuation: taper the dose if therapy must be stopped. - Caution in hepatic impairment: dose adjustment may be necessary. - Use with caution in the elderly: increased sensitivity to blood pressure changes. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Lercanidipine can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Concurrent use with other antihypertensives: risk of excessive hypotension.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may mask tachycardia symptoms. - Diuretics: additive blood pressure‑lowering effect. - Grapefruit juice: may increase drug exposure. - Simvastatin: increased risk of statin‑related muscle toxicity.